RxDoctor Payments DataLook up a doctor →

Brad Herskowitz, MD

Neurology · Miami, FLNPI 1194793950

Payments from drug & device makers

$3,106,372in general payments, 2019–2025

Across 1,552 payments — averaging $2001.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1.4M
  • Sage Therapeutics, LLC$824K
  • AbbVie$312K
  • Pfizer$168K
  • Biohaven Pharmaceuticals, Inc.$98K
  • Biohaven Pharmaceutical Holding Company Ltd.$94K
  • plus $172K from 54 others
$35,505in research payments, 2019–2025

Across 11 payments — averaging $3227.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$26K
  • Eli Lilly$9K

What the payments were for

  • Consulting fees$1,7431%
  • Speaking & faculty fees$237,18287%
  • Travel & lodging$3,2201%
  • Food & beverage$31,28011%
  • Education$730%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly36$1,437,766
Sage Therapeutics, LLC34$823,704
AbbVie(2 entities)339$311,802
Pfizer59$168,469
Biohaven Pharmaceuticals, Inc.67$97,999
Biohaven Pharmaceutical Holding Company Ltd.44$94,108
Lilly USA, LLC84$36,159
Biogen51$36,065
Otsuka Pharmaceutical Development & Commercialization, Inc.2$24,628
Otsuka America Pharmaceutical, Inc.20$14,336
Lundbeck LLC39$13,422
Avanir Pharmaceuticals, Inc.9$11,468
Axsome Therapeutics, Inc.14$10,029
H. Lundbeck A S8$9,413
UCB, Inc.127$4,674
Amgen(2 entities)75$1,631
Neurocrine Biosciences, Inc.67$991
Novartis33$873
Adamas Pharmaceuticals, Inc.67$740
Eisai Inc.29$734
Mallinckrodt Hospital Products Inc.30$641
Teva Pharmaceuticals USA, Inc.34$628
Tanabe Pharma America, Inc.19$407
Harmony Biosciences LLC13$386
Almatica Pharma LLC16$371
Acorda Therapeutics, Inc17$321
SK Life Science, Inc.14$296
Neurelis, Inc.13$239
AstraZeneca(2 entities)11$196
Kyowa Kirin, Inc.11$196
Novo Nordisk AS2$187
Sunovion Pharmaceuticals Inc.9$181
Jazz Pharmaceuticals Inc.8$180
Inspire Medical Systems, Inc.1$172
Argenx US, Inc.8$161
TG Therapeutics, Inc.7$161
Upsher-smith Laboratories LLC8$157
Sumitomo Pharma America, Inc.6$151
Merz Pharmaceuticals, LLC7$149
Scilex Pharmaceuticals Inc.6$145
Johnson & Johnson(2 entities)7$145
Genentech USA, Inc.6$142
Octapharma USA, Inc.6$133
Zyla Life Sciences, Inc.8$123
Takeda Pharmaceuticals U.S.A., Inc.5$121
Grifols USA, LLC6$120
MDD US Operations, LLC6$102
Aprecia Pharmaceuticals, LLC5$97
Livanova USA, Inc.5$95
Boston Scientific3$89
Avion Pharmaceuticals6$87
Amneal Pharmaceuticals LLC4$78
Banner Life Sciences, LLC4$69
GE HealthCare5$66
Aquestive Therapeutics, Inc.3$52
Immedica Pharma US, Inc.2$48
Abbott3$42
Averitas Pharma Inc.1$37
Catalyst Pharmaceuticals, Inc.2$35
Cycle Pharmaceuticals Inc2$34

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,106,372 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$299,942
Medicare patients
300
Services billed
15,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole28$40,288
Nurtec OdtRimegepant Sulfate13$15,770
QuliptaAtogepant14$14,575
Levetiracetam75$2,719
Carbidopa-LevodopaCarbidopa/Levodopa37$2,386
Lacosamide15$2,009
Divalproex Sodium ErDivalproex Sodium15$1,175
Gabapentin98$833
Memantine Hcl23$762
Quetiapine Fumarate36$540
Sumatriptan Succinate36$448
Pregabalin25$414
Topiramate38$350
Primidone26$266
Amitriptyline Hcl11$242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$14,336$40,28828 claims
PfizerNurtec Odt$168,469$15,77013 claims
AbbVieQulipta$311,802$14,57514 claims
Upsher-smith Laboratories LLCTopiramate$157$35038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,434 neurology providers in Florida.

Other neurology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →